Vertex Pharmaceuticals Inc Stock Price, News & Analysis

Vertex Pharmaceuticals and CRISPR Therapeutics announced upcoming oral presentations of clinical data for exagamglogene autotemcel (exa-cel) at the 2022 ASH Annual Meeting. This investigational therapy targets sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Key presentations include efficacy and safety data from Phase 3 trials, with plans for regulatory submissions in the U.S., U.K., and EU by early 2023. The studies highlight the quality of life impacts for patients undergoing treatment.

Vertex Pharmaceuticals (VRTX) and Entrada Therapeutics (TRDA) have announced a global collaboration to develop intracellular EEV therapeutics for myotonic dystrophy type 1 (DM1). Entrada will receive an upfront payment of $224 million along with $26 million in equity and is eligible for future milestone payments totaling up to $485 million. The collaboration focuses on Entrada’s late-stage preclinical candidate, ENTR-701, which aims to address underlying causes of DM1. Vertex will lead further development, manufacturing, and commercialization efforts.

Vertex Pharmaceuticals (NASDAQ: VRTX) will participate in key investor conferences including the Jefferies London Healthcare Conference on November 16, 2022, at 9:10 a.m. GMT and the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 9:15 a.m. EST. Live webcasts of these events will be accessible on Vertex's website. Established in 1989, Vertex focuses on innovative treatments for serious diseases, particularly cystic fibrosis, and has a promising pipeline addressing various serious conditions. For more information, visit www.vrtx.com.

Vertex Pharmaceuticals (NASDAQ: VRTX) has partnered with basketball Hall-of-Famer Alonzo Mourning to launch the "Power Forward" initiative. This educational campaign aims to raise awareness about APOL1-mediated kidney disease (AMKD), emphasizing the significance of early diagnosis and genetic testing. AMKD affects approximately 100,000 individuals in the U.S. and is genetically driven, particularly impacting those of sub-Saharan African ancestry. The initiative offers resources to help at-risk individuals discuss kidney health with healthcare providers.

Vertex Pharmaceuticals (NASDAQ: VRTX) reports promising long-term data on TRIKAFTA^® (elexacaftor/tezacaftor/ivacaftor), showcased at the North American Cystic Fibrosis Conference. The ongoing 192-week study shows sustained improvements in lung function and respiratory symptoms among patients with at least one F508del allele. In children aged 2-5, TRIKAFTA improved lung function and was generally well-tolerated. Vertex plans to submit regulatory applications for this age group. The latest findings reinforce TRIKAFTA's critical role in CF treatment.

Vertex Pharmaceuticals reported Q3 2022 product revenues of $2.33 billion, marking an 18% increase from Q3 2021. The company raised its full-year 2022 product revenue guidance to $8.8 billion to $8.9 billion, driven by strong uptake of TRIKAFTA/KAFTRIO. Net income increased by 9% to $931 million, with a diluted EPS of $3.59. Vertex continues to advance its clinical pipeline, including exa-cel for Sickle Cell Disease and VX-548 for acute pain, while increasing R&D investments.

Vertex Pharmaceuticals (NASDAQ: VRTX) will report its Q3 2022 financial results on October 27, 2022, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss these results, accessible via phone and live webcast on Vertex's website.

Vertex is a leader in biotechnology, focusing on transformative medicines for serious diseases, particularly cystic fibrosis, and has a robust pipeline addressing other conditions like sickle cell disease and type 1 diabetes. The company is recognized as a top employer in the industry.

Vertex Pharmaceuticals (NASDAQ: VRTX) has initiated a first-in-human trial for VX-634, a new AAT corrector for alpha-1 antitrypsin deficiency (AATD). The FDA has approved the IND application for VX-634, marking a significant advancement in the company's AATD program. Alongside this, Vertex plans to launch a 48-week Phase 2 study of VX-864 to evaluate its long-term efficacy in reducing liver polymer levels and increasing functional AAT in plasma. The company will also introduce additional AAT correctors starting in 2023.

Vertex Pharmaceuticals and CRISPR Therapeutics have announced a rolling review of exa-cel by the U.S. FDA for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), with submission starting in November 2022 and completion expected by Q1 2023. Submissions to the EMA and MHRA are also on track for Q4 2022. Exa-cel received multiple designations, including Fast Track and Orphan Drug status. The therapy aims to edit patients' stem cells for improved disease outcomes.